- Home
- IRMD vs PHAR Comparison
IRMD vs PHAR Comparison
Compare IRMD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IRMD | PHAR |
|---|---|---|
| Founded | 1992 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 910.4M | 1.1B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | IRMD | PHAR |
|---|---|---|
| Price | $97.38 | $17.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $72.00 | $38.00 |
| AVG Volume (30 Days) | ★ 77.1K | 26.2K |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 13.00 | N/A |
| EPS | ★ 1.65 | 0.00 |
| Revenue | $80,511,268.00 | ★ $362,274,000.00 |
| Revenue This Year | $15.17 | $25.19 |
| Revenue Next Year | $10.15 | $4.47 |
| P/E Ratio | ★ $59.26 | $3,006.53 |
| Revenue Growth | 12.91 | ★ 26.78 |
| 52 Week Low | $47.48 | $7.50 |
| 52 Week High | $98.53 | $18.30 |
Technical Indicators
Market Signals| Indicator | IRMD | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 65.76 | 51.55 |
| Support Level | $90.92 | $16.55 |
| Resistance Level | $98.53 | $18.30 |
| Average True Range (ATR) | 2.27 | 0.80 |
| MACD | -0.41 | -0.07 |
| Stochastic Oscillator | 85.81 | 41.02 |
Price Performance
Historical ComparisonAbout IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.